Pantoprazole DR Tablets

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-22-D-0141

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Seymour, Indiana, UNITED STATES

SourceSAM
Documents3
The Defense Logistics Agency (DLA) Troop Support has issued an award notice for a national contract pertaining to the supply of Pantoprazole Delayed Release (DR) Tablets, under procurement identifier SPE2D2-22-D-0141. This contract falls under the North American Industry Classification System (NAICS) code 325412, which covers Pharmaceutical Preparation Manufacturing, and is further classified under Product Service Code (PSC) 6505, indicating drugs and biologicals. The primary objective of this procurement is to ensure a reliable and consistent supply of Pantoprazole DR Tablets, a pharmaceutical product widely used for the treatment of gastrointestinal conditions such as gastroesophageal reflux disease (GERD) and other related disorders. The contract is national in scope, reflecting the DLA’s commitment to supporting the medical and pharmaceutical needs of federal agencies and military personnel across the United States. The place of performance for this contract is Seymour, Indiana, indicating that manufacturing, distribution, or fulfillment activities related to this award will be based in this location. Contractors engaged in this opportunity are expected to comply with all relevant federal regulations and quality standards associated with pharmaceutical manufacturing and supply. DLA Troop Support, a federal office, serves as the contracting entity for this award. The agency is responsible for ensuring that the U.S. military and other federal entities have access to essential medical supplies. Key contacts for this procurement include Ryan Ferry ([email protected], 215-737-3182) and Jason Wray ([email protected], 215-737-0614), who can provide further information regarding contract administration and requirements. The notice remains active as of its posting date, January 31, 2022. Interested parties can access additional details and attachments related to this award via the official SAM.gov opportunity listing (Opportunity ID: 8b3061f7dc264ddc81b886e76561a571). This contract represents a significant opportunity for pharmaceutical manufacturers with the capability to produce and deliver Pantoprazole DR Tablets in compliance with federal standards. Contractors should note that the scope and requirements are tailored to ensure national coverage and sustained supply, with a focus on quality, reliability, and regulatory compliance throughout the contract lifecycle.